{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:17:30Z","timestamp":1787944650587,"version":"build-2784847793"},"reference-count":76,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Research and Graduate Studies at King Khalid University","award":["RGP2\/676\/46"],"award-info":[{"award-number":["RGP2\/676\/46"]}]},{"award":["RGP2\/676\/46"],"award-info":[{"award-number":["RGP2\/676\/46"]}],"id":[{"id":"https:\/\/ror.org\/052kwzs30","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Oral targeted therapies now constitute a substantial and growing proportion of anticancer drug therapy, shifting administration from the controlled intravenous setting to patient-managed oral therapy in the outpatient setting, where systemic exposure depends on factors that parenteral therapy largely bypasses. Food effects, gastric pH, first-pass metabolism, transporter activity, organ function, concomitant medications and adherence contribute to variability in exposure, and many oral anticancer agents have narrow therapeutic indices in which modest exposure changes carry clinical consequence. This review synthesizes the pharmacokinetic determinants of oral anticancer drug exposure across twenty-seven exemplar agents spanning the main mechanistic classes and translates them into actionable pharmacy practice. Its contribution is a cross-class agent-level comparison in which within-class divergences are made explicit, the integration of determinants usually reviewed separately, and an explicit statement of the evidence level behind every entry. We examine food effects, the interaction between acid-suppressive therapy and pH-dependent agents, the dominant role of cytochrome P450 3A4 and of the efflux transporters P-glycoprotein and breast cancer resistance protein, and the exposure\u2013response relationships that motivate therapeutic drug monitoring, for which the evidence remains uneven and does not yet support routine use. We propose a structured framework for operationalizing these principles in daily practice.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091082","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:33:52Z","timestamp":1787942032000},"page":"1082","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Food Effects, Pharmacokinetic Drug\u2013Drug Interactions, and Clinical Optimization of Oral Anticancer Agents"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-1331","authenticated-orcid":false,"given":"Abdullah A.","family":"Assiri","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha 61421, Asir, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.drudis.2016.03.002","article-title":"Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors","volume":"21","author":"Willemsen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40262-022-01200-8","article-title":"Considering the oral bioavailability of protein kinase inhibitors: Essential in assessing the extent of drug-drug interaction and improving clinical practice","volume":"62","author":"Puisset","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-024-00939-1","article-title":"Playing hide-and-seek with tyrosine kinase inhibitors: Can we overcome administration challenges?","volume":"26","author":"Kollipara","year":"2024","journal-title":"AAPS J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN Task Force Report: Oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic drug monitoring of oral anticancer drugs: The Dutch Pharmacology Oncology Group\u2013Therapeutic Drug Monitoring protocol for a prospective study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_7","unstructured":"United States Food and Drug Administration (2026, June 01). Clinical Drug Interaction Studies\u2014Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions: Guidance for Industry, Available online: https:\/\/downloads.regulations.gov\/FDA-2017-D-5961-0023\/attachment_1.pdf."},{"key":"ref_8","unstructured":"Gleevec (Imatinib Mesylate) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021588s035lbl.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cpt.610","article-title":"Food effect studies for oncology drug products","volume":"101","author":"Parsad","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","unstructured":"United States Food and Drug Administration (2026, June 01). Evaluation of Gastric pH-Dependent Drug Interactions with Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis."},{"key":"ref_11","unstructured":"Xtandi (Enzalutamide) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/203415s018,213674s005lbl.pdf."},{"key":"ref_12","unstructured":"Erleada (Apalutamide) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210951s016lbl.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1177\/10781552211037976","article-title":"Alternate dosage formulations of oral targeted anticancer agents","volume":"27","author":"Wagner","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cpdd.299","article-title":"Effect of the wetting agent sodium lauryl sulfate on the pharmacokinetics of alectinib: Results from a bioequivalence study in healthy subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2174\/0113894501376271250710221018","article-title":"Therapeutic drug monitoring: A new hope for individualised treatment with venetoclax","volume":"26","author":"Tang","year":"2025","journal-title":"Curr. Drug Targets"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"rgaf095","DOI":"10.1093\/jpp\/rgaf095","article-title":"Pharmacokinetics of pazopanib: A review of the determinants, influencing factors and the clinical importance of therapeutic drug monitoring","volume":"78","author":"Kyriacou","year":"2026","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.2014.87","article-title":"pH-dependent drug-drug interactions for weak base drugs: Potential implications for new drug development","volume":"96","author":"Zhang","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/DDDT.S249098","article-title":"Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors: A review","volume":"14","author":"Zhao","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_20","unstructured":"Zytiga (Abiraterone Acetate) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202379s035lbl.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2008.18.3285","article-title":"Effects of food on the relative bioavailability of lapatinib in cancer patients","volume":"27","author":"Koch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_22","unstructured":"Zelboraf (Vemurafenib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202429s019lbl.pdf."},{"key":"ref_23","unstructured":"Votrient (Pazopanib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022465s028lbl.pdf."},{"key":"ref_24","unstructured":"Tarceva (Erlotinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021743s025lbl.pdf."},{"key":"ref_25","unstructured":"Cabometyx (Cabozantinib) Tablets (2025). Prescribing Information, Exelixis."},{"key":"ref_26","unstructured":"Tafinlar (Dabrafenib) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202806s006lbl.pdf."},{"key":"ref_27","unstructured":"Mekinist (Trametinib) Tablets (2017). Prescribing Information, Novartis Pharmaceuticals."},{"key":"ref_28","unstructured":"Venclexta (Venetoclax) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/208573s031lbl.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_30","unstructured":"Alecensa (Alectinib) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208434s015lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpdd.296","article-title":"Effect of food and esomeprazole on the pharmacokinetics of alectinib, a highly selective ALK inhibitor, in healthy subjects","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_32","unstructured":"Stivarga (Regorafenib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203085s011lbl.pdf."},{"key":"ref_33","unstructured":"Verzenio (Abemaciclib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208716s010s011lbl.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-022-06690-5","article-title":"An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer","volume":"195","author":"Lim","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","unstructured":"Sutent (Sunitinib Malate) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021938s036lbl.pdf."},{"key":"ref_36","unstructured":"Tagrisso (Osimertinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208065s030lbl.pdf."},{"key":"ref_37","unstructured":"Kisqali (Ribociclib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209935s030lbl.pdf."},{"key":"ref_38","unstructured":"Zejula (Niraparib) Capsules\/Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214876s003s004lbl.pdf."},{"key":"ref_39","unstructured":"Sprycel (Dasatinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021986s025lbl.pdf."},{"key":"ref_40","unstructured":"Lynparza (Olaparib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf."},{"key":"ref_41","unstructured":"Afinitor (Everolimus) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022334s016lbl.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-017-3246-4","article-title":"Effect of food on the bioavailability of palbociclib","volume":"79","author":"Plotka","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_43","unstructured":"Ibrance (Palbociclib) Tablets and Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/207103s023lbl.pdf."},{"key":"ref_44","unstructured":"Tasigna (Nilotinib) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022068s035s036lbl.pdf."},{"key":"ref_45","unstructured":"Danziten (Nilotinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/219293s000lbl.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1078155217752535","article-title":"Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing","volume":"25","author":"Yu","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9246","DOI":"10.1002\/cam4.3528","article-title":"Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: A retrospective cohort study from a randomized clinical trial","volume":"9","author":"Tsuda","year":"2020","journal-title":"Cancer Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1200\/JCO.2007.12.0758","article-title":"The value meal: How to save $1700 per month or more on lapatinib","volume":"25","author":"Ratain","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1634\/theoncologist.2020-0044","article-title":"Administration of lapatinib with food increases its plasma concentration in Chinese patients with metastatic breast cancer: A prospective phase II study","volume":"25","author":"Xu","year":"2020","journal-title":"Oncologist"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Becker","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_52","unstructured":"Tykerb (Lapatinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022059s023lbl.pdf."},{"key":"ref_53","unstructured":"Cotellic (Cobimetinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206192s005lbl.pdf."},{"key":"ref_54","unstructured":"Imbruvica (Ibrutinib) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205552s016lbl.pdf."},{"key":"ref_55","unstructured":"Calquence (Acalabrutinib) Capsules (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210259s009lbl.pdf."},{"key":"ref_56","first-page":"409","article-title":"Consequences of hypoacidity induced by proton pump inhibitors\u2014A practical approach","volume":"31","year":"2018","journal-title":"Klin. Onkol."},{"key":"ref_57","unstructured":"Tyverb (Lapatinib) Summary of Product Characteristics, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tyverb-epar-product-information_en.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1208\/s12248-016-9957-3","article-title":"Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib","volume":"18","author":"Parrott","year":"2016","journal-title":"AAPS J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"Peric","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17425255.2019.1559816","article-title":"Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer","volume":"15","author":"Robert","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"Skee","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e13807","DOI":"10.1111\/cts.13807","article-title":"Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor","volume":"17","author":"Salem","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.1750","article-title":"Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects","volume":"61","author":"Lee","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3892\/or.2021.8231","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with poly(ADP-ribose) polymerase inhibitors (Review)","volume":"47","author":"Zhao","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_66","unstructured":"Alecensa (Alectinib) Summary of Product Characteristics, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alecensa-epar-product-information_en.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e70053","DOI":"10.1111\/cts.70053","article-title":"Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management","volume":"17","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-019-00746-4","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in subjects with hepatic impairment","volume":"58","author":"Salem","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_70","unstructured":"Revuforj (Revumenib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218944s003lbl.pdf."},{"key":"ref_71","unstructured":"Gomekli (Mirdametinib) Capsules and Tablets for Oral Suspension (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219379s000lbl.pdf."},{"key":"ref_72","unstructured":"Avmapki Fakzynja Co-Pack (Avutometinib Capsules; Defactinib Tablets) (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219616s000lbl.pdf."},{"key":"ref_73","unstructured":"Inluriyo (Imlunestrant) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218881s000lbl.pdf."},{"key":"ref_74","unstructured":"Hernexeos (Zongertinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219042s000lbl.pdf."},{"key":"ref_75","unstructured":"Hyrnuo (Sevabertinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/219972Orig1s000Lbl.pdf."},{"key":"ref_76","unstructured":"Zegfrovy (Sunvozertinib) Tablets (2026, June 01). Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219839s000lbl.pdf."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1082\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:34:44Z","timestamp":1787942084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":76,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091082"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091082","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}